Diagnostic value of tumor biomarkers CA125 and CA72-4 in differentiation of epithelial ovarian cancer and endometrioma
dc.contributor.author | Mehri, JS | |
dc.contributor.author | Farnaz, S | |
dc.contributor.author | Ali, DT | |
dc.contributor.author | Parvin, MG | |
dc.contributor.author | Elaheh, O | |
dc.contributor.author | Marziyeh, P | |
dc.contributor.author | Parvin, H | |
dc.contributor.author | Parvin, S | |
dc.contributor.author | Mojtaba, Z | |
dc.date.accessioned | 2018-08-26T08:51:46Z | |
dc.date.available | 2018-08-26T08:51:46Z | |
dc.date.issued | 2018 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/53520 | |
dc.description.abstract | Ovarian cancer is the leading cause of gynecological malignancy-related mortality. CA125 level in patients with Epithelial Ovarian Cancer (EOC) and endometrioma can frequently be high. CA72-4 level was also elevated in several carcinomas including ovarian cancer. Due to its lack of specificity, however, this marker has a limited role in the differential diagnosis between EOC and endometrioma. In this research, we studied the levels of biomarkers CA125 and CA72-4 to determine their potential role in the differential diagnosis of endometrioma and EOC. For this goal, biomarkers CA125 and CA72-4 were identified in 75 patients with ovarian cancer and 75 patients with endometrioma. Cut-off levels for CA125 and CA72-4 were considered 35 U/ml and 3.8 U/ml, respectively. The data have been analyzed by SPSS, with a p-value<0.05 considered significant. Both markers CA125 and CA72-4 were remarkably elevated in EOC (p=0.001). Areas under the ROC curve for CA125 and CA72-4, with sensitivity of 0.48 and specificity of 0.52, were 0.633 and 0.624, respectively. The differences were not significant. It has been shown that CA125 and CA72-4 serum levels are elevated in patients with EOC; however, this did not lead to detection of malignancy. This means that CA72-4 level does not demonstrate a significant difference in malignancy diagnoses when compared to the use of CA125 alone. é 2018, Scientific Publishers of India. All rights reserved. | |
dc.language.iso | English | |
dc.relation.ispartof | Biomedical Research (India) | |
dc.subject | CA 125 antigen | |
dc.subject | CA 72-4 antigen | |
dc.subject | adolescent | |
dc.subject | adult | |
dc.subject | aged | |
dc.subject | area under the curve | |
dc.subject | Article | |
dc.subject | cancer staging | |
dc.subject | controlled study | |
dc.subject | diagnostic value | |
dc.subject | endometrium tumor | |
dc.subject | female | |
dc.subject | histopathology | |
dc.subject | human | |
dc.subject | major clinical study | |
dc.subject | ovary carcinoma | |
dc.subject | prospective study | |
dc.subject | protein blood level | |
dc.subject | protein function | |
dc.subject | receiver operating characteristic | |
dc.subject | sensitivity and specificity | |
dc.title | Diagnostic value of tumor biomarkers CA125 and CA72-4 in differentiation of epithelial ovarian cancer and endometrioma | |
dc.type | Article | |
dc.citation.volume | 29 | |
dc.citation.issue | 8 | |
dc.citation.spage | 1697 | |
dc.citation.epage | 1701 | |
dc.citation.index | Scopus |